Stephens reissued their overweight rating on shares of OraSure Technologies, Inc. (NASDAQ:OSUR) in a research note published on Tuesday, July 11th. The brokerage currently has a $19.00 target price on the medical instruments supplier’s stock, up from their previous target price of $14.00.
Several other research firms have also commented on OSUR. Jefferies Group LLC boosted their price target on OraSure Technologies from $16.00 to $19.00 and gave the stock a buy rating in a research report on Wednesday, June 28th. Canaccord Genuity upped their target price on OraSure Technologies from $15.00 to $18.00 and gave the company a buy rating in a research report on Wednesday, June 28th. Finally, Zacks Investment Research raised OraSure Technologies from a hold rating to a buy rating and set a $18.00 target price on the stock in a research report on Saturday, May 6th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $14.89.
Shares of OraSure Technologies (NASDAQ OSUR) traded up 3.50% on Tuesday, reaching $18.63. 497,270 shares of the company’s stock traded hands. OraSure Technologies has a 52 week low of $6.37 and a 52 week high of $19.33. The stock has a market capitalization of $1.08 billion, a price-to-earnings ratio of 35.69 and a beta of 1.56. The stock’s 50-day moving average price is $16.71 and its 200-day moving average price is $12.95.
OraSure Technologies (NASDAQ:OSUR) last released its quarterly earnings results on Wednesday, May 3rd. The medical instruments supplier reported $0.21 EPS for the quarter, topping the consensus estimate of $0.17 by $0.04. The firm had revenue of $32.55 million for the quarter, compared to analyst estimates of $31.19 million. OraSure Technologies had a return on equity of 16.06% and a net margin of 22.57%. OraSure Technologies’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.04 EPS. Equities analysts predict that OraSure Technologies will post $0.43 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This report was first posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://transcriptdaily.com/2017/07/24/stephens-reaffirms-overweight-rating-for-orasure-technologies-inc-osur-updated.html.
In other news, CEO Douglas A. Michels sold 290,495 shares of the stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $16.75, for a total value of $4,865,791.25. Following the completion of the transaction, the chief executive officer now owns 894,012 shares of the company’s stock, valued at $14,974,701. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Douglas A. Michels sold 361,216 shares of the stock in a transaction on Monday, May 8th. The stock was sold at an average price of $15.08, for a total value of $5,447,137.28. Following the completion of the transaction, the chief executive officer now directly owns 881,620 shares of the company’s stock, valued at approximately $13,294,829.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,220,134 shares of company stock valued at $18,789,795. 7.80% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Victory Capital Management Inc. acquired a new position in OraSure Technologies during the first quarter valued at about $100,000. Profund Advisors LLC purchased a new position in shares of OraSure Technologies during the first quarter valued at $137,000. BNP Paribas Arbitrage SA boosted its position in shares of OraSure Technologies by 977.2% in the first quarter. BNP Paribas Arbitrage SA now owns 10,718 shares of the medical instruments supplier’s stock valued at $139,000 after buying an additional 9,723 shares in the last quarter. Private Advisor Group LLC boosted its position in shares of OraSure Technologies by 7.1% in the first quarter. Private Advisor Group LLC now owns 10,923 shares of the medical instruments supplier’s stock valued at $135,000 after buying an additional 723 shares in the last quarter. Finally, Capital Fund Management S.A. purchased a new position in shares of OraSure Technologies during the first quarter valued at $144,000. 88.65% of the stock is owned by institutional investors.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.